Therapeutics – The vision of healing metabolic diseases

The Need for innovative therapeutics

Today metabolic diseases are considered to be “chronic progressive”. This simply means that until now no one has found a therapy that can stop them, or even reverse them.

The main reason for this is that the treatment focusses on certain secondary and concomitant parameters, like elevated blood glucose, elevated blood values and others. It is of course, important to reduce these more symptomatic parameters, as they pose risks in themselves. However, they are not the underlying cause of the metabolic disorder.

Our break-through approach

We, instead, look at the mRNAs as the drivers of pathology of metabolic disorders. mRNAs are instrumental in the genesis of disbalances of the energy metabolism. Many of these disbalances have their origin in the subcutaneous adipose tissue (SAT) which has grown dysfunctional over lifetime. Among the influencing factors that lead to these disbalances are age, environmental factors, life-style, and as well hazard.

Our therapy concepts address the mRNAs of the SAT. They enable to rebalance a dysfunctional into an again healthy and functional SAT that can fulfil its role within an effective and healthy energy metabolism.

Our solutions

Lipocyte develops new therapy concepts based on gene expression analyses of the SAT. Unhealthy patterns of mRNA-clusters are rebalanced by targeted and time-restricted interventions.

Therapy-concepts range from administrations on protein-level to rebalancing mRNA-levels through ncRNAs. These concepts are targeted, addressing specific disorders and diseases. In the long run we plan as well to develop a broader therapy concept aiming at revitalising the SAT in general with a broader effect on a range of metabolic diseases.

We will develop therapy concepts in-house to preclinical level. Further trials will be concluded in co-operations.

The first therapy concepts will enter preclinical stage in 2024.